Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure

Phase 1

Withdrawn

Brief Summary: This study explores a potential drug-drug interaction between istaroxime and digoxin in patients with stable CHF on chronic oral digoxin treatment.

Detailed Description: This is a single center, randomized, double blind, placebo controlled, escalating dose phase I interaction study. The three dose levels of istaroxime or placebo will be randomized sequentially to three cohorts (I to III) of 16 patients each (12 patients on istaroxime and 4 patients on placebo). Digoxin will be administered non blinded in all patients, once daily in the morning after a standardized breakfast, continuing with previously personalized dosage schedule during the screening period, treatment period, post treatment period and follow up period. Prior to accrual of cohorts II and III, a Data Monitoring Committee (DMC) will advise on the continuation to the next istaroxime dose, based on a predetermined safety review.

This 37 day study includes a screening period (Days -21 to -1), a treatment period (Day 1), a post treatment period (Days 2-4), and a follow up period (which includes one patient visit on Day 14). Patients will be confined in the phase I research center from Day -2 to Day 4.

Recruitment & Eligibility

Inclusion Criteria

Main screening inclusion criteria :

Signed informed consent;
Male or female patients ≥18 years;
Female patients of childbearing potential must not be pregnant;
Chronic stable cardiac function impairment (no change in heart failure medication over the last 3 months and without any dosage adjustment in the last 4 weeks);
Systolic blood pressure (SBP) of ≥ 90 mmHg and ≤ 140 mmHg;
LVEF ≤ 35% by any method (to be performed at screening if not measured within the last 12 months);
Chronic treatment (i.e. once daily dosing without interruption) with oral digoxin started at least 3 months prior to study entry and without any concomitant administration of other positive inotropic drugs;

Exclusion Criteria

Main screening exclusion criteria :

Need for current or intermittent intravenous positive inotrope administration within the preceding 6 months, or hemodynamic support devices;
Acute coronary syndrome within the past 3 months;
Coronary artery bypass graft or percutaneous coronary intervention within the past 3 months;
Stroke within the past 6 months;
Atrial fibrillation or uncontrolled heart rate (HR) (> 100 beats per minute [bpm]);
Significant arrhythmia or second or third degree atrio-ventricular block;
Valvular disease as the primary cause of HF;
Significant ECG abnormalities as assessed by appropriately qualified physician or investigator including QTcF >450;
Positive testing for Human Immunodeficiency Virus (HIV), Hepatitis B and/or Hepatitis C;

Main randomization exclusion criteria:

HR > 100 bpm or < 50 bpm;
Serum potassium > 5.3 mmol/L or < 3.8 mmol/L and magnesium > 1.1 mmol/L or < 0.6 mmol/L,
TN I > ULN.

Arm && Interventions

Primary Outcome Measures

Name	Time	Method
Pharmacodynamic endpoints: - Change in echocardiographic parameters; - Change in SBP; - Change in non invasive cardiac output (Impedance cardiography) parameters.
Pharmacokinetic endpoints : Istaroxime PK parameters: - Istaroxime and Istaroxime metabolites (PST2915/2922/3093) plasma concentrations - Istaroxime and Istaroxime metabolites (PST2915/2922/3093) urine concentrations
Pharmacokinetic endpoints : Digoxin PK parameters: - Digoxin plasma concentrations
Safety endpoints: - Incidence of adverse events; - Change in vital signs; - Change in 12-lead ECG parameters; - Incidence of clinically or hemodynamically significant episodes of supraventricular or ventricular arrhythmias detected by continuous EC

Secondary Outcome Measures

Name	Time	Method

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial